Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: Results of a prospective observational analysis

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 9, 2012, Pages 953-963

  Metzke, Barbara ^a   Neubauer, Werner Christian ^a   Hieke, Stefanie ^a   Jung, Manfred ^b   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adverse events; Drug interactions; Haematology oncology patients; Pharmacoepidemiology; Systemic antifungal drugs

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; AMLODIPINE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BILIRUBIN; CASPOFUNGIN; CREATININE; CYCLOSPORIN; DEXAMETHASONE; DIGOXIN; FLUCONAZOLE; GLIBENCLAMIDE; METOCLOPRAMIDE; NITRENDIPINE; PANTOPRAZOLE; PHENYTOIN; POSACONAZOLE; PREDNISOLONE; PREDNISONE; VORICONAZOLE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; CLINICAL PRACTICE; CONFUSION; CREATININE BLOOD LEVEL; DRUG ERUPTION; DRUG SAFETY; DRUG USE; ELECTROLYTE DISTURBANCE; FEMALE; HALLUCINATION; HEMATOLOGY; HUMAN; HYPOCALCEMIA; HYPONATREMIA; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; NAUSEA AND VOMITING; NEPHROTOXICITY; OBSERVATIONAL STUDY; ONCOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; FEMALE; HEMATOLOGY; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MYCOSES; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84865863182     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3278     Document Type: Article

References (35)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
2. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173: 707-717.
3. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56(Suppl 1): i5-i11.
4. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
6. Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008; 14: 5-24.
7. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-2266.
8. de With K, Steib-Bauert M, Knoth H, et al. Hospital use of systemic antifungal drugs. BMC Clin Pharmacol 2005; 5: 1.
9. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-666.
10. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637.
11. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369-388.
12. Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43: e29-38.
13. Lipp HP. Antifungal agents--clinical pharmacokinetics and drug interactions. Mycoses 2008; 51: 7-18.
14. Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010; 53: 95-113.
15. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005; 56: 286-290.
16. Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 2004; 33: 137-152.
17. Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M. Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer 2009; 124: 722-728.
18. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592-600.
19. Raad, II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42: 1726-1734.
20. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
21. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
22. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155-1163.
23. Micromedex 1.0 Healthcare Series TR. http://www.thomsonhc.com. 2011.
24. Cha R, Sobel JD. Fluconazole for the treatment of candidiasis: 15years experience. Expert Rev Anti Infect Ther 2004; 2: 357-366.
25. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 2005; 14: 755-767.
26. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
27. R Development Core Team R. A Language and Environment for Statistical Computing. ISBN 3-900051-07-0. http://wwwR-projectorg: (accessed July 2011).
28. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
29. Epaulard O, Saint-Raymond C, Villier C, et al. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect 16: 1362-1364.
30. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 146: 300-304.
31. Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-1458.
32. Egger SS, Meier S, Leu C, et al. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant 2010; 45: 1197-1203.
33. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004; 6: 110-116.
34. Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684.
35. Neubauer WC, Engelhardt M, König A, et al. Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother 2010; 54: 4029-4032.